More recently, use of microarray technology showed significant differences of gene patterns in skin biopsies from patients with diffuse and limited SSc, which also differed from normal controls.
Microarray technology shows great potential but previous studies were limited by small number of samples in the colorectal cancer (CRC) research.
During the past few years, analysis of animal transcriptomes with the DNA microarray technology showed that many aspects of physiology are directly controlled by the circadian clock through control of the expression of enzymes and regulators involved in these physiological processes [ 5, 6].
Recently, some studies have compared microarray and MPSS technology, showing that there is moderate correlation between the two platforms but that one technology will often detect expression for some genes that are not measured by the other platform [ 22- 24].
At least one study has compared microarray and sequencing technology, showing that data in the latter are highly replicable and that the sequencing technology can detect differentially expressed genes between two samples at a higher positive discovery rate (Marioni et al., 2008).
Microarray technology has shown promise in predicting outcome in these patients.
In the past few years, protein chip and microarray technology has shown its great potential in the functional analysis of the proteome, clinical diagnostics and drug discovery.
Recent reports, using DNA microarray technology, have shown that the MIC-1 gene is more highly expressed in prostate cancer than in BPH tissues (Buckhaults et al, 2001; Welsh et al, 2001).
Recent advances in microarray technology have shown that subgroups of ALL as well as acute myeloid leukaemia (AML) can be accurately distinguished based on their gene expression profiles [ 10- 16].
Significant expression level changes between these two samples detected only by microarray technology were shown by 4,149 transcripts, resulting in a combined differential tumour epithelial transcriptome of 8,051 genes.
